In India, Roche’s Herceptin Strategy Collides With Mylan
This article was originally published in PharmAsia News
Executive Summary
On an appeal from Mylan, patent authorities in Kolkata warned Roche to respond within 10 days on the status of its Herceptin divisional patents or claims will be deemed to be withdrawn and abandoned.